CKD Bio Balance Sheet Health
Financial Health criteria checks 2/6
CKD Bio has a total shareholder equity of ₩131.6B and total debt of ₩157.3B, which brings its debt-to-equity ratio to 119.5%. Its total assets and total liabilities are ₩320.2B and ₩188.6B respectively.
Key information
119.5%
Debt to equity ratio
₩157.25b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩12.35b |
| Equity | ₩131.58b |
| Total liabilities | ₩188.59b |
| Total assets | ₩320.17b |
Recent financial health updates
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30Financial Position Analysis
Short Term Liabilities: A063160's short term assets (₩136.1B) exceed its short term liabilities (₩87.3B).
Long Term Liabilities: A063160's short term assets (₩136.1B) exceed its long term liabilities (₩101.3B).
Debt to Equity History and Analysis
Debt Level: A063160's net debt to equity ratio (110.1%) is considered high.
Reducing Debt: Insufficient data to determine if A063160's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if A063160 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A063160 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 12:22 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CKD Bio Corp. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyung-rae Han | Daishin Securities Co. Ltd. |
| Sang-Hun Lee | iM Securities |
| Han Kyung Kim | LS Securities Co., Ltd. |